Composition of active agents to positively affect a robust mammalian endocannabinoid system tone to better address age related discomfort
US11684600B2 · kind B2 · utility
0Cited by
0References
18Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Mar 4, 2021 |
| Grant date | Jun 27, 2023 |
| Priority date | — |
| Expiry date | Aug 19, 2041 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K47/02
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Compositions and methods for prophylactically sustaining and/or maintaining a robust endocannabinoid system in patients for modulating excess inflammatory response and inflammatory diseases over the mammalian lifespan to mitigate age-related discomfort. Specifically, a method of treating inflammatory and neuropathic pain in a mammal by administering a synergistic pharmaceutical daily dosage form comprising: palmitoylethanolamide (PEA), beta-caryophyllene (BCP) and docosahexaenoic acid (DHA).
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.